Advancing Cell Therapy for Heart Failure: BioCardia Announces CardiAMP HF II Trial Begins with First Patient
BioCardia announced the enrollment of the first patient in their Phase 3 CardiAMP HF II clinical trial, which is evaluating their lead cell therapy for heart failure. This trial will assess the safety and effectiveness of the autologous cell therapy, which uses a patient’s own bone marrow cells delivered to the heart to potentially stimulate healing. The study builds on previous trials […]
First in US to Treat Heart Failure with Umbilical Cord Stem Cells
The University of Louisville (UofL) is conducting a groundbreaking Phase II clinical trial called CATO, which represents several significant firsts in heart failure treatment[1][3]: Trial Characteristics The CATO trial is a randomized, double-blind, placebo-controlled study that will enroll 60 patients across three centers: UofL, the University of Miami, and Texas Heart Institute[3]. The study focuses […]
BioCardia Completes Phase III Clinical Trial of Autologous Stem Cell Therapy for Ischemic Heart Failure
BioCardia, Inc., a leader in cellular therapies for cardiovascular diseases, has announced the completion of its pivotal Phase III trial for CardiAMP®, an autologous cell therapy designed to treat ischemic heart failure with reduced ejection fraction (HFrEF). This milestone marks the last patient follow-up in the double-blind, placebo-controlled trial, which aims to assess the safety […]
Immorta Bio Inc. Announces Breakthrough in Liver Failure Treatment with Stem Cell Technology
Immorta Bio Inc., a company focused on longevity and regenerative medicine, has announced a significant breakthrough in the treatment of liver failure. The company is developing personalized stem cell technologies that show great promise in combating various diseases of aging. Immorta Bio’s research pipeline includes Personalized Regenerative Cells (PRCs), Personalized Mesenchymal Stem Cells (pMSCs), and […]
Revolutionizing Heart Health With The Promising Role of Stem Cell Therapy in Cardiology
Can the key to unlocking the future of heart health lie within our very own cells? Stem cell therapy represents a burgeoning frontier in medical science, especially in the realm of cardiology. This innovative approach could potentially revolutionize the way we treat heart disease, offering hope where conventional treatments may fall short. What are Stem […]
BioCardia Unveils Groundbreaking Results in Phase III CardiAMP Cell Therapy for Heart Failure
BioCardia, Inc., a leader in biotechnological advancements for cardiovascular diseases, recently announced remarkable interim results from its Phase III CardiAMP® Cell Therapy trial for treating advanced chronic heart failure. These findings mark a significant milestone in the pursuit of innovative treatments for heart failure, showcasing the potential of stem cell therapy to revolutionize patient care. […]
The Dawn of a New Era in Heart Failure Treatment: BioCardia’s CardiAMP Heart Failure II Phase 3 Pivotal Study
In an exciting development for the field of cardiovascular medicine, BioCardia, Inc., a pioneering biotechnology company, has announced the activation of the CardiAMP Heart Failure II Phase 3 pivotal study. This groundbreaking study, recently greenlit by the FDA, represents a significant leap forward in the treatment of ischemic heart failure through advanced cell therapy techniques. […]
Induced Pluripotent Stem Cells (iPSCs) for Treating Heart Failure
Overview of Heart Failure Heart failure, a condition affecting millions worldwide, is a complex clinical syndrome resulting from any structural or functional impairment of ventricular filling or ejection of blood. It’s a leading cause of hospitalization in people over the age of 65, underscoring a significant health and economic burden. Despite advancements in pharmacological and […]
BioCardia Announces FDA Approval for Groundbreaking Heart Failure Treatment
BioCardia, Inc., a prominent player in the development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases, has recently announced a significant milestone. The U.S. Food and Drug Administration (FDA) has approved the Phase III clinical trial protocol for BioCardia’s CardiAMP autologous cell therapy. This therapy is designed for patients suffering from ischemic heart […]